Lv4
800 积分 2021-09-02 加入
In vivo manufacture and manipulation of CAR-T cells for better druggability
13天前
已完结
Acute myeloid leukaemia
24天前
已完结
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
25天前
已完结
HLA-independent T cell receptors for targeting tumors with low antigen density
26天前
已完结
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
27天前
已完结
Integrative proteogenomic and pharmacological landscape of acute myeloid leukaemia
27天前
已完结
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
27天前
已完结
Allogeneic “Off-the-Shelf” CAR T Cells: Challenges and Advances
1个月前
已完结
Phenotype and function of human B cells expressing CD70 (CD27 ligand)
1个月前
已完结
Autologous CD7 CAR T cells generated without T-cell pre-selection in pediatric patients with relapsed/refractory T-ALL: a phase I trial
1个月前
已完结
皖公网安备34019202002308
